Effects of muscarinic and adrenergic agonism on auditory P300 in the macaque

Physiology and Behavior

Volumn 70, Issue 1-2, 2000, Pages 163-170

  O'Neill, Joseph ^a,b   Halgren, Eric ^c   Marinkovic, Ksenija ^c   Siembieda, Douglas ^a   Refai, Daniel ^a   Fitten, L Jaime ^a,b   Perryman, Kent ^a   Fisher, Abraham ^d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

AF102B; Evoked potentials; Guanfacine; Muscarinic agonist; Noradrenergic agonist; P300; Primates

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; CEVIMELINE; GUANFACINE; MUSCARINIC AGENT; PROTEIN P300; RECEPTOR SUBTYPE;

ADRENERGIC SYSTEM; AMPLITUDE MODULATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUDITORY STIMULATION; BINDING SITE; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; EVOKED AUDITORY RESPONSE; FEMALE; MACACA; NONHUMAN; PRIORITY JOURNAL;

EID: 0034661088     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-9384(00)00258-4     Document Type: Article

References (49)

1. Antal A., Bodis-Wollner I., Ghilardi M.F., Glover A., Mylin L., Toldi J. The effect of levo-acetyl-carnitine on visual cognitive evoked potentials in the behaving monkey. EEG Clin Neurophysiol. 86:1993;268-274.
2. Antal A., Kovanecz I., Bodis-Wollner I. Visual discrimination and P300 are affected in parallel by cholinergic agents in the behaving monkey. Physiol Behav. 56:1994;161-166.
3. Arnsten A.F.T., Cai J.X., Goldman-Rakic P.S. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects. evidence for alpha-2 receptor subtypes J Neurosci. 8:1988;4287-4298.
4. Arnsten A.F.T., Contant T.A. Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task. Psychopharmacology (Berlin). 108:1992;159-169.
5. Arnsten A.F.T., Goldman-Rakic P.S. Noradrenergic mechanisms in age-related cognitive decline. J Neural Transm Suppl. 24:1987;317-324.
6. Arnsten A.F.T., Steere J.C., Hunt R.D. The contribution of α2-noradrenergic mechanisms to prefrontal cortical cognitive function. Arch Gen Psychiatry. 53:1996;448-455.
7. Arthur D.L., Starr A. Task-relevant late positive component of the auditory event-related potential in monkeys resembles P300 in humans. Science. 223:1985;186-188.
8. Blackwood D.H.R., Christie J.E. The effects of physostigmine on memory and auditory P300 in Alzheimer-type dementia. Biol Psychiatry. 21:1986;557-560.
9. Bondareff W., Mountjoy C.Q., Roth M. Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology. 32:1982;164-168.
10. Callaway E., Halliday R., Naylor H., Schechter G. Effects of oral scopolamine on human stimulus evaluation. Psychopharmacology (Berlin). 85:1985;133-138.
11. Callaway E., Halliday R., Naylor H., Brandeis D. Clonidine and scopolamine. differences and similarities in how they change human information processing Prog Neuropychopharmacol Biol Psychiatry. 15:1991;497-502.
12. Coull J.T. Pharmacological manipulations of the α2-noradrenergic system. Drugs Aging. 5:1994;116-126.
13. Donchin E. Event-related potential. a tool in the study of human information processing Begleiter H. Evoked Brain Potentials and Behavior. 1978;13-88 Plenum Press, New York.
14. Duncan CC, Kaye WH. Effects of clonidine on event-related potential measures of information processing. In: Johnson R Jr, Rohrbaugh JW, Parasuraman R, editors. Current Trends in Event-Related Potential Research. EEG Suppl 1987;40:527-31.
15. Fisher A., Heldman E. ±) cis-2-methyl-spiro(1,3-oxathiolane-5,3′) quinnuclidine (AF102B) a new M1 agonist as a rational treatment strategy in Alzheimer's disease - an overview. Nagatsu T., Fisher A., Yoshida M. Basic, Clinical and Therapeutic Aspects of Alzheimer's and Parkinson's Diseases, vol. 35B. 1991;309-319 Plenum Press, New York.
16. Fisher A., Heldman E., Haring R., Meshulam H., Pittel Z., Gurwitz D., Marciano D., Brandeis R., Sapir M., Karton Y., Sadot E., Barg Y., Pinkas-Kramarski R., Vogel Z., Ginzburg I., Treves T.A., Verchovsky R., Klimowsky S., Korczyn A.D. New M1 agonists. from replacement treatment to delaying the progression of Alzheimer's disease - novel properties Life Sci Res. 972:1993;221-235.
17. Fooden J. Taxonomy and Evolution of the Sinica Group of Macaques. 2. Species and Subspecies of the Indian Bonnet Macaque, Macaca radiata. Feldiana Zoology, New Series, No. 9:1979;Field Museum of Natural History, Chicago.
18. Glover A., Ghilardi M.F., Bodis-Wollner I., Onofrj M. Alterations in event-related potentials (ERPs) of MPTP-treated monkeys. EEG Clin Neurophysiol. 71:1988;461-468.
19. Glover A.A., Onofrj M.C., Ghilardi M.F., Bodis-Wollner I. P300-like potentials in the normal monkey using classical conditioning and an auditory "oddball" paradigm. EEG Clin Neurophysiol. 65:1986;231-235.
20. Hammond E.J., Meador K.J., Aung-Din R., Wilder B.J. Cholinergic modulation of human P3 event-related potentials. Neurology. 37:1987;346-350.
21. Hillyard S.A., Kutas M. Electrophysiology of cognitive processing. Annu Rev Psychol. 34:1983;33-61.
22. Joseph K.C., Sitaram N. The effect of clonidine on auditory P300. Psychiatr Res. 28:1989;255-262.
23. Kása P., Rakonczay Z., Gulya K. The cholinergic system in Alzheimer's disease. Prog Neurobiol. 52:1997;511-535.
24. Katznelson R.D. EEG recording, electrode placement, and aspects of generator localization. Nunez P.L. Electric Fields of the Brain. 1981;176-213 Oxford University Press; New York.
25. Ladner C.J., Lee J.M. Pharmacological drug treatment of Alzheimer disease. the cholinergic hypothesis revisited J Neuropathol Exp Neurol. 57:1998;718-731.
26. Maurer K., Dierks T., Strik W.K., Fröhlich L. P3 topography in psychiatry and psychopharmacology. Brain Topogr. 3:1990;79-84.
27. Maurer K., Riederer P., Heinsen H., Beckmann H. Altered P300 topography due to functional and structural disturbances in the limbic system in dementia and psychoses and to pharmacological conditions. Psychiatry Res. 29:1989;391-393.
28. Meador K.J., Loring D.W., Patel B.R., Dacis H.C. Central cholinergic systems and the P3 evoked potential. Int J Neurosci. 33:1987;199-205.
29. Neville H.J., Foote S.L. Auditory event-related potentials in the squirrel monkey. parallels to human late wave response Brain Res. 298:1984;107-116.
30. O'Neill J., Fitten L.J., Siembieda D., Crawford K.C., Halgren E., Fisher A., Refai D. Divided attention-enhancing effects of AF102B and THA in aging monkeys. Psychopharmacology (Berlin). 143:1999;123-130.
31. O'Neill J., Fitten L.J., Siembieda D., Halgren E., Kim E., Fisher A., Perryman K. Effects of AF102B and tacrine on delayed match-to-sample in monkeys. Prog Neuropychopharmacol Biol Psychiatr. 22:1998;665-678.
32. Onofrj M., Ghilardi M.F., Faricelli A., Bodis-Wollner I., Calvani M. Effect of levo-acetylcarnitine on P300-like potentials of the normal monkey. Drugs Exp Clin Res. III:1987;407-415.
33. Paller K.A. The neural substrates of cognitive event-related potentials. a review of animal models of P3 Heinze H.-J., Münte H.T., Mangun G.R. Cognitive Electrophysiology. 1994;Birkhäuser, Boston.
34. Paller K.A., McCarthy G., Roessler E., Allison T., Wood C.C. Potentials evoked in human and monkey medial temporal lobe during auditory and visual oddball paradigms. EEG Clin Neurophysiol. 84:1992;269-279.
35. Paller K.A., Zola-Morgan S., Squire L.R., Hillyard S.A. P3-like brain waves in normal monkeys and in monkeys with medial temporal lesions. Behav Neurosci. 102:1988;714-725.
36. Perry E.K., Tomlinson B.E., Blessed G., Perry R.H., Cross A.J., Crow T.J. Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. J Neurol Sci. 51:1981;279-287.
37. Pineda J.A., Foote S.L., Neville H.J. Long-latency event-related potentials in squirrel monkeys. further characterization of wave form morphology, topography, and functional properties EEG Clin Neurophysiol. 67:1987;77-90.
38. Pineda J.A., Foote S.L., Neville H.J. Effects of locus coeruleus lesions on auditory, long-latency, event-related potentials in monkey. J Neurosci. 9:1989;81-93.
39. Pineda J.A., Swick D. Visual P3-like potentials in squirrel monkey. effects of a noradrenergic agonist Brain Res Bull. 28:1992;485-491.
40. Pineda J.A., Westerfield M. Monkey P3 in an "oddball" paradigm. pharmacological support for multiple neural sources Brain Res Bull. 31:1993;689-696.
41. Picton T.W., Campbell K.B., Baribeau-Braun J., Proulx G.B. The neurophysiology of human attention. a tutorial review Requin J. Attention and performance VIII. 1978;Lawrence Earlbaum, Hillsdale, NJ.
42. Polich J. P300 in the evaluation of aging and dementia. EEG Clin Neurophysiol Suppl. 42:1998;304-323.
43. Rugg M.D., Potter D.D., Pickles C.D., Roberts R.C. Effects of scopolamine on the modulation of event-related brain potentials by word repetition. Soc Neurosci Abstr. 15:1989;245.
44. Shimohama S., Taniguchi T., Fujiwara M., Kameyama M. Biochemical characterization of alpha adrenergic receptors in the human brain and changes in Alzheimer-type dementia. J Neurochem. 47:1986;1294-1301.
45. Squires N.K., Squires K.C., Hillyard S.A. Two varieties of long-latency positive waves evoked by unpredictable auditory stimuli in man. EEG Clin Neurophysiol. 38:1975;387-401.
46. Swick D., Pineda J.A., Foote S.L. Effects of systemic clonidine on auditory event-related potentials in squirrel monkeys. Brain Res Bull. 33:1994;79-86.
47. Swick D., Pineda J.A., Schacher S., Foote S.L. Locus coeruleus neuronal activity in awake monkeys. relationship to auditory P300-like potentials and spontaneous EEG Exp Brain Res. 101:1994;86-92.
48. Testa G., Angelini C. Studio preliminare sull'uso dell'acetilcarnitina in pazienti con deterioramento mentale. Riv Neurol. 50:1982;185.
49. van Gool W.A., Waardenburg J., Meyjes F.E.P., Weinstein H.C., de Wilde A. The effect of terahydroaminoacridine (THA) on P300 in Alzheimer's disease. Biol Psychiatry. 30:1991;953-957.